What smart money is saying about Dianthus Therapeutics Inc
1 fund in our archive has pitched Dianthus Therapeutics Inc — most recently Artisan Non-U.S. Small-Mid Growth Strategy in March 2026.
Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was established in 2015 and operates from its headquarters in New York, New York.
Position history
Between Q1 2026 and Q2 2026, 1 fund letter reported a position in Dianthus Therapeutics Inc — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 1 | 0 | 0 |
| Q1 2026 | 0 | 0 | 0 | 1 |
Fund activity · 1 position · 1 move
- New positionTimesSquare U.S. Small Cap Growth StrategyJune 2026
“One of the new positions we initiated this quarter is Dianthus Therapeutics, a clinical-stage biotechnology company developing novel complement-pathway antibodies for severe autoimmune and neuromuscular diseases, led by its lead candidate DNTH103.”
Read the letterDianthus Therapeutics Inc
Fund coverage · 1 thesis
Dianthus Therapeutics develops complement antibodies with strong Phase 3 momentum and pipeline-in-a-product optionality supporting multibillion-dollar potential.
Read the full thesis
Read every full thesis on Dianthus Therapeutics Inc
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→